Dawn Hershman, MD, MS, Professor of Medicine and Epidemiology at Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, discusses how the cost of breast cancer treatment is directly associated with rates of adherence, and explains why financial factors matter in treatment decisions.

Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the benefits of clinical trial participation for patients with cancer.

Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.

Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.

Dr Modi discusses the basis, clinical significance, and findings of the DESTINY-Breast04 trial of DS-8201a therapy for HER2-low breast cancer.

Novel BTK Inhibitor Shows Promising for Mantle Cell Lymphoma by HMP Global

Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, spoke with Oncology Learning Network about data that was presented regarding the use of DS-8201a in the treatment of HER2-positive breast cancer.

Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about advancements made in the treatment of patients with early stage, HER2-positive breast cancer.

Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the HER2CLIMB study and the promising role of tucatinib in the treatment of metastatic, HER2-positive breast cancer.

Jonathan Trent, MD, PhD, Professor and Associate Director for Clinical Research, Sylvester Comprehensive Cancer Center, University of Miami, Florida discusses the evolution of the current treatment landscape for tenosynovial giant cell tumors.